Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

ClinicalTrials.gov ID: NCT00054717

Public ClinicalTrials.gov record NCT00054717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low-dose Ritonavir (TPV/RTV) Verses Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Demonstrate the safety and efficacy of Tipranavir/Ritonavir versus an active treatment regimen in highly treatment experienced Human Immunodeficiency virus 1(HIV-1) infected patients.

Study identification

NCT ID
NCT00054717
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
630 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2003 (Type not available)
Primary completion
Sep 2008 (Actual)
Completion
Not listed
Last update posted
Jul 2, 2014

Started 2003

United States locations

U.S. sites
96
U.S. states
33
U.S. cities
70
Facility City State ZIP Site status
1182.12.62 Boehringer Ingelheim Investigational Site Phoenix Arizona — —
1182.12.108 El Rio SIA Tucson Arizona — —
1182.12.9 Boehringer Ingelheim Investigational Site Berkeley California — —
1182.12.23 Boehringer Ingelheim Investigational Site Beverly Hills California — —
1182.12.12 Boehringer Ingelheim Investigational Site Fountain Valley California — —
1182.12.76 Boehringer Ingelheim Investigational Site Long Beach California — —
1182.12.1 Boehringer Ingelheim Investigational Site Los Angeles California — —
1182.12.59 David Geffen School of Medicine at UCLA Los Angeles California — —
1182.12.82 Boehringer Ingelheim Investigational Site Los Angeles California — —
1182.12.97 Boehringer Ingelheim Investigational Site Los Angeles California — —
1182.12.69 UC Davis Medical Center Sacramento California — —
1182.12.89 Boehringer Ingelheim Investigational Site San Diego California — —
1182.12.99 Boehringer Ingelheim Investigational Site San Diego California — —
1182.12.25 Boehringer Ingelheim Investigational Site San Francisco California — —
1182.12.5 Boehringer Ingelheim Investigational Site San Francisco California — —
1182.12.53 Boehringer Ingelheim Investigational Site San Francisco California — —
1182.12.98 University of Colorado Health Sciences Center Denver Colorado — —
1182.12.7 Boehringer Ingelheim Investigational Site Norwalk Connecticut — —
1182.12.103 Boehringer Ingelheim Investigational Site Washington D.C. District of Columbia — —
1182.12.52 Boehringer Ingelheim Investigational Site Washington D.C. District of Columbia — —
1182.12.70 Washington D.C. District of Columbia — —
1182.12.79 Boehringer Ingelheim Investigational Site Fort Lauderdale Florida — —
1182.12.77 Boehringer Ingelheim Investigational Site Fort Myers Florida — —
1182.12.45 Boehringer Ingelheim Investigational Site Miami Florida — —
1182.12.75 CARES Resource Miami Florida — —
1182.12.85 Boehringer Ingelheim Investigational Site Miami Florida — —
1182.12.93 Boehringer Ingelheim Investigational Site Miami Beach Florida — —
1182.12.17 Boehringer Ingelheim Investigational Site Orlando Florida — —
1182.12.90 Boehringer Ingelheim Investigational Site Sarasota Florida — —
1182.12.63 Boehringer Ingelheim Investigational Site Tampa Florida — —
1182.12.78 Boehringer Ingelheim Investigational Site Tampa Florida — —
1182.12.94 Infectious Disease Research Institute Tampa Florida — —
1182.12.67 Boehringer Ingelheim Investigational Site Vero Beach Florida — —
1182.12.123 Infectious Disease Clinics of Emory Atlanta Georgia — —
1182.12.88 Boehringer Ingelheim Investigational Site Atlanta Georgia — —
1182.12.72 Boehringer Ingelheim Investigational Site Decatur Georgia — —
1182.12.47 Boehringer Ingelheim Investigational Site Macon Georgia — —
1182.12.8 Family Practice Medical Center Boise Idaho — —
1182.12.105 Boehringer Ingelheim Investigational Site Chicago Illinois — —
1182.12.3 Boehringer Ingelheim Investigational Site Chicago Illinois — —
1182.12.49 Boehringer Ingelheim Investigational Site Chicago Illinois — —
1182.12.32 Boehringer Ingelheim Investigational Site Indianapolis Indiana — —
1182.12.48 Boehringer Ingelheim Investigational Site Indianapolis Indiana — —
1182.12.33 Boehringer Ingelheim Investigational Site Lexington Kentucky — —
1182.12.44 Boehringer Ingelheim Investigational Site Louisville Kentucky — —
1182.12.95 Boehringer Ingelheim Investigational Site New Orleans Louisiana — —
1182.12.81 Boehringer Ingelheim Investigational Site Portland Maine — —
1182.12.30 Boehringer Ingelheim Investigational Site Baltimore Maryland — —
1182.12.6 Boehringer Ingelheim Investigational Site Bethesda Maryland — —
1182.12.100 Boehringer Ingelheim Investigational Site Boston Massachusetts — —
1182.12.101 Boehringer Ingelheim Investigational Site Boston Massachusetts — —
1182.12.41 Boehringer Ingelheim Investigational Site Boston Massachusetts — —
1182.12.61 Boehringer Ingelheim Investigational Site Springfield Massachusetts — —
1182.12.13 University of Michigan Health System Ann Arbor Michigan — —
1182.12.54 Boehringer Ingelheim Investigational Site Detroit Michigan — —
1182.12.56 Boehringer Ingelheim Investigational Site Detroit Michigan — —
1182.12.120 Department of Medicine, HIV/AIDS Program Minneapolis Minnesota — —
1182.12.14 Dybedal Center for Clinical Research Kansas City Missouri — —
1182.12.87 Boehringer Ingelheim Investigational Site St Louis Missouri — —
1182.12.11 Wellness Center Las Vegas Nevada — —
1182.12.4 Boehringer Ingelheim Investigational Site Camden New Jersey — —
1182.12.21 Boehringer Ingelheim Investigational Site East Orange New Jersey — —
1182.12.40 Boehringer Ingelheim Investigational Site Santa Fe New Mexico — —
1182.12.68 Boehringer Ingelheim Investigational Site Albany New York — —
1182.12.34 Boehringer Ingelheim Investigational Site Mount Vernon New York — —
1182.12.119 Boehringer Ingelheim Investigational Site New York New York — —
1182.12.22 Boehringer Ingelheim Investigational Site New York New York — —
1182.12.36 Boehringer Ingelheim Investigational Site New York New York — —
1182.12.58 Beth Israel Medical Center New York New York — —
1182.12.96 Boehringer Ingelheim Investigational Site New York New York — —
1182.12.107 Boehringer Ingelheim Investigational Site Rochester New York — —
1182.12.83 Boehringer Ingelheim Investigational Site Stony Brook New York — —
1182.12.43 Boehringer Ingelheim Investigational Site Valhalla New York — —
1182.12.42 Boehringer Ingelheim Investigational Site Durham North Carolina — —
1182.12.46 Boehringer Ingelheim Investigational Site Huntersville North Carolina — —
1182.12.109 Boehringer Ingelheim Investigational Site Akron Ohio — —
1182.12.24 Boehringer Ingelheim Investigational Site Cincinnati Ohio — —
1182.12.35 Boehringer Ingelheim Investigational Site Cleveland Ohio — —
1182.12.65 Ohio State University Medical Center Columbus Ohio — —
1182.12.80 Infectious Disease Institute Clinical Trials Unit Oklahoma City Oklahoma — —
1182.12.114 Pinnacle Health Harrisburg Pennsylvania — —
1182.12.28 University of Pennsylvania Philadelphia Pennsylvania — —
1182.12.50 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania — —
1182.12.86 The Miriam Hospital Providence Rhode Island — —
1182.12.10 Boehringer Ingelheim Investigational Site Columbia South Carolina — —
1182.12.116 Greenville Hospital System Greenville South Carolina — —
1182.12.2 Boehringer Ingelheim Investigational Site Memphis Tennessee — —
1182.12.106 Boehringer Ingelheim Investigational Site Dallas Texas — —
1182.12.55 Boehringer Ingelheim Investigational Site Dallas Texas — —
1182.12.31 Boehringer Ingelheim Investigational Site Houston Texas — —
1182.12.73 Boehringer Ingelheim Investigational Site Houston Texas — —
1182.12.26 Boehringer Ingelheim Investigational Site San Antonio Texas — —
1182.12.91 Boehringer Ingelheim Investigational Site Annandale Virginia — —
1182.12.122 VCU Health Systems Richmond Virginia — —
1182.12.15 Boehringer Ingelheim Investigational Site Seattle Washington — —
1182.12.29 Boehringer Ingelheim Investigational Site Milwaukee Wisconsin — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00054717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 2, 2014 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00054717 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →